The company in question is, Kite Pharma, Inc. (NASDAQ:KITE) currently with a stock price of 49.95 (-2.86% today). The market cap for Kite Pharma, Inc. is 2547.35, and is in the sector Healthcare, and Biotechnology industry. The target price for Kite Pharma, Inc. is 73.09. Currently Kite Pharma, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Kite Pharma, Inc. is 806.78 and so far today it is 326096.
Performance in the last year for Kite Pharma, Inc. has been -14.87%. For EPS growth, Kite Pharma, Inc. has seen a growth of -21.80%, and is looking to grow in the next year to -11.90%. More long term stats show that EPS growth has been *TBA over the last five years and could be *TBA for the next five years. Kite Pharma, Inc. has seen sales growth quarter over quarter at -34.20%, with EPS growth quarter over quarter at -58.10%. The 20-day simple moving average is -13.21%, with the 200-day simple moving average coming to -2.85%.
Since the IPO date for Kite Pharma, Inc. on the 6/20/2014, Kite Pharma, Inc. has seen performance year to date to be -16.55%. With Kite Pharma, Inc. trading at 49.95, the dividend yield is *TBA, and the EPS is -3.68.
So could Kite Pharma, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 128.01 and the P/B is at 4.63. The P/cash is 4.8, with P/free cash flow at *TBA.
Kite Pharma, Inc. ability to deal with debt shows that the current ratio is 12.6, and the quick ratio is 12.6. This is with long term debt/equity at 0, and total debt/equity at 0.
In terms of margins, Kite Pharma, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Kite Pharma, Inc. is *TBA. Return on assets come to -28.10% with return on investment coming to -16.80%.
Insider ownership for Kite Pharma, Inc., is at 1.30% and institutional ownership comes to 80.90%. Outstanding shares are at 49.54. While shares float is 44.51. The float short is currently 13.77%, and short ratio is 7.6.